MX2019000047A - Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras. - Google Patents
Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras.Info
- Publication number
- MX2019000047A MX2019000047A MX2019000047A MX2019000047A MX2019000047A MX 2019000047 A MX2019000047 A MX 2019000047A MX 2019000047 A MX2019000047 A MX 2019000047A MX 2019000047 A MX2019000047 A MX 2019000047A MX 2019000047 A MX2019000047 A MX 2019000047A
- Authority
- MX
- Mexico
- Prior art keywords
- synuclein
- alpha
- peptide inhibitors
- based peptide
- synuclein aggregation
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 238000004220 aggregation Methods 0.000 title abstract 2
- 230000002776 aggregation Effects 0.000 title abstract 2
- 102000003802 alpha-Synuclein Human genes 0.000 title 1
- 108090000185 alpha-Synuclein Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000003942 amyloidogenic effect Effects 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000010256 myopathy, lactic acidosis, and sideroblastic anemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La presente invención se relaciona con péptidos inhibidores que se unen a moléculas de a-sinucleína y que inhiben la acumulación amiloidogénica de a-sinucleína, la citotoxicidad de a-sinucleína y la propagación de la a-sinucleína. Se describen métodos para fabricar y usar los péptidos inhibidores (por ejemplo, para tratar sujetos con afecciones o enfermedades que se encuentran mediadas por a-sinucleína, tal como enfermedad de Parkinson, demencia con cuerpos de Lewy o AMS).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356410P | 2016-06-29 | 2016-06-29 | |
| PCT/US2017/040106 WO2018005867A2 (en) | 2016-06-29 | 2017-06-29 | Structure-based peptide inhibitors of alpha-synuclein aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000047A true MX2019000047A (es) | 2019-07-04 |
Family
ID=60786477
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000047A MX2019000047A (es) | 2016-06-29 | 2017-06-29 | Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras. |
| MX2023009652A MX2023009652A (es) | 2016-06-29 | 2019-01-07 | Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009652A MX2023009652A (es) | 2016-06-29 | 2019-01-07 | Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10815271B2 (es) |
| EP (1) | EP3478311A4 (es) |
| JP (3) | JP6968839B2 (es) |
| KR (2) | KR20230109776A (es) |
| CN (2) | CN109641028A (es) |
| CA (1) | CA3029676A1 (es) |
| IL (1) | IL263913B2 (es) |
| MX (2) | MX2019000047A (es) |
| RU (1) | RU2766711C2 (es) |
| WO (1) | WO2018005867A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10563681B2 (en) | 2011-12-21 | 2020-02-18 | Deka Products Limited Partnership | System, method, and apparatus for clamping |
| CN109641028A (zh) * | 2016-06-29 | 2019-04-16 | 加利福尼亚大学董事会 | α-突触核蛋白聚集的基于结构的肽抑制剂 |
| EP3596102B1 (en) | 2017-03-15 | 2025-09-10 | The Regents of the University of California | Structure-based peptide inhibitors that target the tau vqiink fibrillization segment |
| EP4149505A1 (en) | 2020-05-15 | 2023-03-22 | Vib Vzw | Means and methods for the treatment of pathological aggregation |
| EP3943947A1 (en) * | 2020-07-22 | 2022-01-26 | Universitat Autònoma de Barcelona | Inhibitors of alpha-synuclein aggregation and uses thereof |
| CN116457466A (zh) * | 2020-09-23 | 2023-07-18 | 西洛斯治疗有限公司 | 用于抑制α-突触核蛋白聚集的组合物和方法 |
| CA3207656A1 (en) * | 2021-02-08 | 2022-08-11 | University Of British Columbia | Anti-synucleinopathy peptide and methods to treat neurodegenerative diseases |
| EP4071165A1 (en) | 2021-04-05 | 2022-10-12 | Consejo Superior de Investigaciones Científicas (CSIC) | A new non-aggregative splicing isoform of human tau is decreased in alzheimer s disease |
| US20240238366A1 (en) * | 2021-05-11 | 2024-07-18 | O-Force Co., Ltd. | alpha-SYNUCLEIN AGGREGATION INHIBITOR, PHARMACEUTICAL COMPOSITION FOR alpha-SYNUCLEIN DISEASE, AND USE THEREOF |
| CN114645052B (zh) * | 2021-07-01 | 2023-05-26 | 中国医学科学院医学生物学研究所 | 一种全脑过表达核易位人源α-突触核蛋白转基因鼠的高效构建方法 |
| KR102793149B1 (ko) * | 2021-11-24 | 2025-04-09 | 주식회사 윙스타바이오 | 아밀로이드 전구체 단백질에 대한 저해 활성을 갖는 펩타이드 및 이의 용도 |
| EP4186918A1 (en) | 2021-11-30 | 2023-05-31 | Université de Rennes | Inhibitory peptides for the diagnostic and/or treatment of tauopathies |
| WO2023108290A1 (en) * | 2021-12-15 | 2023-06-22 | The Governing Council Of The University Of Toronto | Peptide inhibitors and methods for inhibiting protein aggregation in neurons and neurodegenerative diseases |
| KR20230131017A (ko) * | 2022-03-04 | 2023-09-12 | 삼성전자주식회사 | 가속기에 대해 온-디멘드 체크포인트를 수행하는 전자 장치 및 그 동작 방법 |
| DE102022105391A1 (de) | 2022-03-08 | 2023-09-14 | Forschungszentrum Jülich GmbH | Entwicklung eines α-Synuclein Amyloidtracers |
| WO2023181070A1 (en) * | 2022-03-23 | 2023-09-28 | Council Of Scientific & Industrial Research | PEPTIDE TO TREAT α-SYNUCLEIN AMYLOID BASED DISORDERS |
| US11932594B1 (en) | 2023-10-31 | 2024-03-19 | King Faisal University | 8-((2-hydroxy-5-methylphenyl)diazenyl)naphthalene-1,3-disulfonic acid as an antioxidant compound |
| KR20250085855A (ko) | 2023-12-04 | 2025-06-13 | 성균관대학교산학협력단 | 퇴행성 신경 질환 가속 전파 모델 및 이의 제조방법 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7186501A (en) * | 2000-07-07 | 2002-01-21 | Panacea Pharmaceuticals Inc | Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| GB0216972D0 (en) * | 2002-07-22 | 2002-08-28 | Univ Lancaster | Peptides and peptide derivaties for the treatment of &-synuclein-related diseases |
| US20070213253A1 (en) * | 2003-06-22 | 2007-09-13 | Koji Sode | Synuclein Mutant Having Aggregation-Inhibitory Activity |
| JP2009542611A (ja) * | 2006-07-03 | 2009-12-03 | ザパロイド・リミテッド | アルファ−シヌクレイン凝集の阻害 |
| CN101501694B (zh) * | 2006-08-04 | 2011-11-30 | 英国龙沙生物医药股份有限公司 | 用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法 |
| ES2439490T3 (es) * | 2007-01-05 | 2014-01-23 | University Of Zurich | Anticuerpo anti-beta amiloide y usos del mismo |
| GB0716885D0 (en) * | 2007-08-30 | 2007-10-10 | United Arab Emirates Universit | Diagnostic agent |
| AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| US8754034B2 (en) * | 2009-02-06 | 2014-06-17 | The Regents Of The University Of California | Structure-based design of peptide inhibitors of amyloid fibrillation |
| HRP20160385T1 (hr) * | 2009-03-09 | 2016-05-06 | Ramot At Tel-Aviv University Ltd. | Pripravci za prevenciju i liječenje neurodegenerativnih bolesti |
| WO2012068405A2 (en) * | 2010-11-17 | 2012-05-24 | Isis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| GB201106118D0 (en) | 2011-04-12 | 2011-05-25 | Gripple Ltd | Ground stabilising device |
| CN102504016B (zh) * | 2011-12-08 | 2014-05-28 | 清华大学 | 淀粉样蛋白纤维性寡聚体构象型抗原表位多肽及其应用 |
| CN105636977A (zh) | 2013-05-08 | 2016-06-01 | 加利福尼亚大学董事会 | 作为癌症治疗的新方法的p53聚集的基于结构的肽抑制剂 |
| US20170266257A1 (en) * | 2014-09-25 | 2017-09-21 | Oxeia Biopharmaceuticals, Inc. | Methods of treating traumatic brain injury |
| CN109641028A (zh) * | 2016-06-29 | 2019-04-16 | 加利福尼亚大学董事会 | α-突触核蛋白聚集的基于结构的肽抑制剂 |
-
2017
- 2017-06-29 CN CN201780051045.3A patent/CN109641028A/zh active Pending
- 2017-06-29 RU RU2019102202A patent/RU2766711C2/ru active
- 2017-06-29 CA CA3029676A patent/CA3029676A1/en active Pending
- 2017-06-29 EP EP17821295.7A patent/EP3478311A4/en active Pending
- 2017-06-29 CN CN202310477400.0A patent/CN116650617A/zh active Pending
- 2017-06-29 KR KR1020237023052A patent/KR20230109776A/ko not_active Ceased
- 2017-06-29 WO PCT/US2017/040106 patent/WO2018005867A2/en not_active Ceased
- 2017-06-29 US US16/311,593 patent/US10815271B2/en active Active
- 2017-06-29 MX MX2019000047A patent/MX2019000047A/es unknown
- 2017-06-29 IL IL263913A patent/IL263913B2/en unknown
- 2017-06-29 KR KR1020197002859A patent/KR102554448B1/ko active Active
- 2017-06-29 JP JP2018568852A patent/JP6968839B2/ja active Active
-
2019
- 2019-01-07 MX MX2023009652A patent/MX2023009652A/es unknown
-
2020
- 2020-05-26 US US16/883,515 patent/US11390646B2/en active Active
-
2021
- 2021-10-27 JP JP2021175108A patent/JP7337132B2/ja active Active
-
2022
- 2022-06-24 US US17/848,736 patent/US20230069905A1/en active Pending
-
2023
- 2023-08-22 JP JP2023134385A patent/JP2023162287A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210002329A1 (en) | 2021-01-07 |
| CN116650617A (zh) | 2023-08-29 |
| US20190241613A1 (en) | 2019-08-08 |
| IL263913A (en) | 2019-01-31 |
| JP2023162287A (ja) | 2023-11-08 |
| EP3478311A4 (en) | 2021-01-06 |
| IL263913B1 (en) | 2024-09-01 |
| KR20190034214A (ko) | 2019-04-01 |
| KR102554448B1 (ko) | 2023-07-11 |
| RU2766711C2 (ru) | 2022-03-15 |
| WO2018005867A3 (en) | 2018-02-01 |
| US10815271B2 (en) | 2020-10-27 |
| KR20230109776A (ko) | 2023-07-20 |
| JP6968839B2 (ja) | 2021-11-17 |
| WO2018005867A2 (en) | 2018-01-04 |
| CA3029676A1 (en) | 2018-01-04 |
| JP2022025103A (ja) | 2022-02-09 |
| RU2019102202A3 (es) | 2020-10-30 |
| RU2019102202A (ru) | 2020-07-29 |
| US20230069905A1 (en) | 2023-03-09 |
| IL263913B2 (en) | 2025-01-01 |
| MX2023009652A (es) | 2023-08-24 |
| EP3478311A2 (en) | 2019-05-08 |
| CN109641028A (zh) | 2019-04-16 |
| JP7337132B2 (ja) | 2023-09-01 |
| US11390646B2 (en) | 2022-07-19 |
| JP2019524685A (ja) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023009652A (es) | Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras. | |
| JOP20220245A1 (ar) | أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة | |
| PH12019500494A1 (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
| MX2020003190A (es) | Degradadores de proteinas y usos de los mismos. | |
| EP4272834A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| WO2017011820A3 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| GEP20207151B (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
| MX2023005484A (es) | Analogos de carbamoil fenilalaninol y usos de los mismos. | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| EA201892008A1 (ru) | Соединения и способы лечения неврологических и сердечно-сосудистых состояний | |
| PH12019500751A1 (en) | Carbamoyl phenylalaninol compounds and uses thereof | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| SA519410320B1 (ar) | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| EA202091524A1 (ru) | Ингибиторы рецептора, активируемого протеазой 2 | |
| MX393805B (es) | Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. | |
| ZA202105101B (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
| WO2016150415A8 (de) | Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz | |
| EA201990393A1 (ru) | Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств |